• facebook
  • twitter
  • linked in
  • google+
back top

Shen Christopher - Managing Partner

Shen Christopher

Qiming Venture Partners
Los Altos, United States of America

Christopher Shen MD, is a Managing Partner at Qiming Venture Partners USA, based in Los Altos, CA. Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. He has worked with seven companies that have since gone public or been successfully acquired, worth over US$2.1 billion in value. Notable past investments include Twelve (acquired by Medtronic), Entellus Medical (acquired by Stryker), Nellix Endovascular (acquired by ELGX), Bridgepoint Medical (acquired by BSC), Evalve (acquired by Abbott), Glycomimetics (IPO), Ivantis, and Moximed.

Previously, Dr. Shen worked at Essex Woodlands, a healthcare-focused venture capital and private equity firm. Prior to joining Essex, he worked at New Enterprise Associates, one of the largest diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation’s Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer Inc.’s Strategic Innovation Group, an internal medical technology incubator.

Dr. Shen is the US Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He is also an Adjunct Professor at Stanford Business School. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his MD, MBA, MS in Biomechanical Engineering and BS in Biological Sciences all from Stanford University.